Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N. Hospital MA, et al. Blood. 2014 Aug 21;124(8):1312-9. doi: 10.1182/blood-2014-01-549212. Epub 2014 Jul 8. Blood. 2014. PMID: 25006122 Free article. Clinical Trial.
Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML.
Hospital MA, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, Bourhis JH, Reman O, de Revel T, Terré C, Preudhomme C, Fenaux P, Michallet M, Socié G, Dombret H. Hospital MA, et al. Bone Marrow Transplant. 2012 Nov;47(11):1436-41. doi: 10.1038/bmt.2012.49. Epub 2012 Mar 19. Bone Marrow Transplant. 2012. PMID: 22426749 Clinical Trial.
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D. Jacque N, et al. Among authors: hospital ma. Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17. Blood. 2015. PMID: 26186940 Free PMC article.
Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, Hospital MA, Tamburini J, Delabesse E, Manenti S, Sarry JE, Récher C. Larrue C, et al. Among authors: hospital ma. Blood. 2016 Feb 18;127(7):882-92. doi: 10.1182/blood-2015-05-646497. Epub 2015 Aug 18. Blood. 2016. PMID: 26286850 Free article.
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S; French AML Intergroup ALFA/FILO. Fodil S, et al. Among authors: hospital ma. Leuk Lymphoma. 2021 Jul;62(7):1756-1760. doi: 10.1080/10428194.2021.1881505. Epub 2021 Feb 17. Leuk Lymphoma. 2021. PMID: 33596765 No abstract available.
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S. Bertoli S, et al. Among authors: hospital ma. Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706. Oncotarget. 2015. PMID: 26515730 Free PMC article.
FLT3 inhibitors: clinical potential in acute myeloid leukemia.
Hospital MA, Green AS, Maciel TT, Moura IC, Leung AY, Bouscary D, Tamburini J. Hospital MA, et al. Onco Targets Ther. 2017 Feb 3;10:607-615. doi: 10.2147/OTT.S103790. eCollection 2017. Onco Targets Ther. 2017. PMID: 28223820 Free PMC article. Review.
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Pagliardini T, Castagna L, Harbi S, Porta MD, Rey J, Fürst S, Bramanti S, Saillard C, Legrand F, Maisano V, Faucher C, Granata A, Hospital MA, Lining W, Weiller PJ, Calmels B, Charbonnier A, Lemarie C, Chabannon C, Vey N, Mokart D, Blaise D, Devillier R. Pagliardini T, et al. Among authors: hospital ma. Biol Blood Marrow Transplant. 2019 Sep;25(9):1803-1809. doi: 10.1016/j.bbmt.2019.05.014. Epub 2019 May 22. Biol Blood Marrow Transplant. 2019. PMID: 31128325 Free article. Clinical Trial.
53 results